The Regulatory effect of chlorogenic acid on gut-brain function and its mechanism: A systematic review

Chlorogenic acid (CGA) is a phenolic compound that is widely distributed in honeysuckle, Eucommia, fruits and vegetables. It has various biological functions, including cardiovascular, nerve, kidney, and liver protection, and it exerts a protective effect on human health, according to clinical research and basic research. The intestine and brain are two important organs that are closely related in the human body. The intestine is even called the "second brain" in humans. However, among the many reports in the literature, an article systematically reporting the regulatory effects and specific mechanisms of CGA on the intestines and brain has not been published. In this context, this review uses the regulatory role and mechanism of CGA in the intestine and brain as the starting point and comprehensively reviews CGA metabolism in the body and the regulatory role and mechanism of CGA in the intestine and brain described in recent years. Additionally, the review speculates on the potential biological actions of CGA in the gut-brain axis. This study provides a scientific theory for CGA research in the brain and intestines and promotes the transformation of basic research and the application of CGA in food nutrition and health care.

Pycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy

PURPOSE

The growing numbers of diabetes cases in the developed world are followed by increasing numbers of people diagnosed with diabetic complications. Diabetic microangiopathies in the eye lead to the development of retinopathy involving gradual loss of vision. Previous studies with Pycnogenol showed effectiveness for stopping progression of preproliferative stages of retinopathy. The aim of our study was to show protective effects of Pycnogenol in early stages of retinopathy, characterized by mild to moderate retinal edema in the absence of hemorrhages or hard exudates in the macula center.

METHODS

Following treatment with Pycnogenol (24 patients) for 3 months, retinal edema score (dilated ophthalmology) and retinal thickness (high resolution ultrasound) showed statistically significant improvement as compared to the placebo group (22 patients), which showed negligible changes to baseline. Laser Doppler flow velocity measurements at the central retinal artery showed a statistically significant increase from 34 to 44 cm/s in the Pycnogenol group as compared to marginal effects in the control group.

RESULTS

The major positive observation of this study is the visual improvement, which was subjectively perceived by 18 out of 24 patients in the Pycnogenol group. Testing of visual acuity using the Snellen chart showed a significant improvement from baseline 14/20 to 17/20 already, after 2 months treatment, whereas no change was found in the control group.

CONCLUSIONS

Pycnogenol taken at this early stage of retinopathy may enhance retinal blood circulation accompanied by regression of edema, which favorably improves vision of patients.